Acinetobacter baumannii has been a dreadful problem for ICU physicians for a long time. Bacteremic pneumonia (BP) caused by this organism has a higher mortality compared to other organisms. Between 2012 and 2015, 86 BP and 89 non-bacteremic pneumonia (NBP) patients from five ICUs were enrolled into the study. The 7-day and 14-day mortality rates were higher in BP patients than in NBP patients (P < 0.001). Procalcitonin elevation, high APACHEII score and recent surgery, were independently associated with BP episodes. Acute respiratory distress syndrome, coma, high APACHEII score and procalcitonin elevation, were independently associated with mortality in the BP group. Extensively drug-resistant isolates were detected in 34.9% of BP and 25.8% of NBP isolates. PFGE identified 12 and 9 genotypes in the BP and NBP isolates, respectively, with 6 genotypes shared by both groups. ST195 was the most prevalent type (40%), followed by ST457 (18.9%). The pandemic clonal complex 92 was predominant, accounting for 94.3% of the strains. For all studied periods, mortality remained higher in the BP than the NBP group. Disease severity was the main risk factor for high mortality in the BP group, and other factors related to mortality were infection, and not treatment or microbiology-related.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5681499PMC
http://dx.doi.org/10.1038/s41598-017-13148-yDOI Listing

Publication Analysis

Top Keywords

non-bacteremic pneumonia
8
pneumonia caused
8
acinetobacter baumannii
8
nbp patients
8
bacteremic non-bacteremic
4
caused acinetobacter
4
baumannii icus
4
icus south
4
south china
4
china clinical
4

Similar Publications

Systematic literature review of cost-effectiveness analyses of adult 15- and 20-valent pneumococcal vaccines.

Vaccine

February 2025

Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT, USA; IDEAS Center, Veterans Affairs Salt Lake City Healthcare System, Salt Lake City, UT, USA. Electronic address:

Article Synopsis
  • The review examined cost-effectiveness analyses of new adult pneumococcal vaccines (PCV15 and PCV20) across different countries.
  • Most studies found that PCV20 offered cost savings or was more cost-effective than older vaccination strategies in high-income countries.
  • Assumptions about vaccine effectiveness, duration of protection, and herd immunity effects varied, with most studies considered low-risk for bias.
View Article and Find Full Text PDF

Background: (pneumococcus) causes invasive pneumococcal disease (IPD) and non-invasive acute respiratory infections (ARIs). Three pneumococcal conjugate vaccines (PCVs) are recommended in the United States with additional products in clinical trials. We aimed to estimate 1) proportions of IPD cases and pneumococcal ARIs caused by serotypes targeted by existing and pipeline PCVs and 2) annual U.

View Article and Find Full Text PDF

Introduction: This study analyzed the health and economic impact of the 21-valent pneumococcal conjugate vaccine (V116) and the 20-valent pneumococcal conjugate vaccine (PCV20), as well as their relative cost-effectiveness, in Japanese adults aged 65 years using a delta pricing approach.

Methods: A Markov model was employed to simulate the movement of the Japanese population among four health states: healthy, pneumococcal disease (consisting of invasive pneumococcal disease [IPD] with or without meningitis and non-bacteremic pneumococcal pneumonia [NBPP]), post-meningitis sequelae, and death. The model was populated with publicly available demographic and epidemiologic data, stratified by risk level.

View Article and Find Full Text PDF
Article Synopsis
  • In June 2021, ACIP recommended new vaccination strategies for adults 65 and older or 19-64 with high risk for pneumococcal disease, shifting from previous PPSV23 and PCV13 guidelines to using PCV20 alone or a series of PCV15 and PPSV23.
  • This study conducted a cost-effectiveness analysis comparing the new vaccine strategies against older recommendations to see their financial and health impacts.
  • Results indicated that using PCV20 or PCV15 with PPSV23 for the age-based group was cost-saving, while combining risk-based and age-based vaccinations with PCV20 alone also proved cost-saving. However, using PCV15 with PPSV23 increased quality
View Article and Find Full Text PDF

Introduction: Given the recent approval and recommendation of V116, a 21-valent pneumococcal conjugate vaccine (PCV), in the United States (US), we evaluated the cost-effectiveness of using V116 versus the 20-valent PCV (PCV20) or the 15-valent PCV (PCV15) in series with the 23-valent pneumococcal polysaccharide vaccine (PPSV23) among adults aged ≥ 65 years in the US who had never received a PCV previously.

Methods: A static multi-cohort state-transition Markov model was developed to estimate the lifetime incremental clinical and economic impact of V116 vs. PCV20 or PCV15 + PPSV23 from the societal perspective.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!